The combination of neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic indicator in patients with recurrent pancreatic cancer

9Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: We retrospectively investigated the relationship between prognosis and combined neutrophil-to-lymphocyte ratio (NLR) and serum carbohydrate antigen 19-9 (CA19-9) levels in patients with recurrent pancreatic cancer. Patients and Methods: We enrolled 66 patients whose pancreatic cancer recurred. Results: Based on ROC analysis results, the patients were divided into NLRHigh (NLR ≥1.69) or NLRLow (NLR <1.69), and into CA19-9High (CA19-9 ≥107.95 U/ml) or CA19-9Low (CA19-9 <107.95 U/ml). When the patients were grouped by combined NLR and CA19-9, their 2-year survival rates were NLRLow/CA19-9Low: 58.7%; NLRLow/CA19-9High or NLRHigh/CA19-9Low (grouped together): 11.2%; and NLRHigh/CA19-9High: 0% (p<0.0001). Finally, in multivariate analysis, the combination of NLR and serum CA19-9 level was an independent prognostic factor in patients with recurrent pancreatic cancer. Conclusion: The combination of NLR and serum CA19-9 level is a useful prognostic indicator for recurrent pancreatic cancer.

Cite

CITATION STYLE

APA

Sakamoto, T., Saito, H., Uchinaka, E., Morimoto, M., Amisaki, M., Tokuyasu, N., … Fujiwara, Y. (2018). The combination of neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic indicator in patients with recurrent pancreatic cancer. Anticancer Research, 38(9), 5497–5503. https://doi.org/10.21873/anticanres.12883

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free